Aaron K. Olson

ORCID: 0000-0002-5237-400X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cardiac Ischemia and Reperfusion
  • Connective tissue disorders research
  • Kawasaki Disease and Coronary Complications
  • Mechanical Circulatory Support Devices
  • Glycosylation and Glycoproteins Research
  • Cardiovascular Function and Risk Factors
  • Congenital Heart Disease Studies
  • Thyroid Disorders and Treatments
  • Cardiovascular Issues in Pregnancy
  • Galectins and Cancer Biology
  • Coronary Artery Anomalies
  • Cardiomyopathy and Myosin Studies
  • Aortic Disease and Treatment Approaches
  • Neuroscience of respiration and sleep
  • Cardiac Valve Diseases and Treatments
  • Vascular anomalies and interventions
  • Muscle Physiology and Disorders
  • Mitochondrial Function and Pathology
  • Metabolism, Diabetes, and Cancer
  • Carbohydrate Chemistry and Synthesis
  • Nitric Oxide and Endothelin Effects
  • Congenital heart defects research
  • Cardiovascular Effects of Exercise
  • Cardiac Arrest and Resuscitation
  • Signaling Pathways in Disease

Seattle Children's Hospital
2014-2025

Sandia National Laboratories
2021-2025

Boehringer Ingelheim (United States)
2024

University of Washington
2013-2023

Washington Center
2022

Seattle University
2012-2014

University of Minnesota
2012

University of Utah
2012

University of Alabama at Birmingham
2012

Children's Hospital of Los Angeles
2010

AMP-activated protein kinase (AMPK) has been shown to inhibit cardiac hypertrophy. Here, we show that submaximal AMPK activation blocks cardiomyocyte hypertrophy without affecting downstream targets previously suggested be involved, such as p70 ribosomal S6 kinase, calcineurin/nuclear factor of activated T cells (NFAT) and extracellular signal-regulated kinases. Instead, is accompanied by increased O-GlcNAcylation, which reversed activation. Decreasing O-GlcNAcylation inhibitors the...

10.1038/s41467-017-02795-4 article EN cc-by Nature Communications 2018-01-19

In the adult heart, regulation of fatty acid oxidation and mitochondrial genes is controlled by PPARgamma coactivator-1 (PGC-1) family transcriptional coactivators. However, in response to pathological stressors such as hemodynamic load or ischemia, cardiac myocytes downregulate PGC-1 activity preference for glucose metabolism pathways. Interestingly, despite reduced activity, these are associated with biogenesis, at least initially. The transcription factors that regulate changes setting...

10.1172/jci38331 article EN Journal of Clinical Investigation 2010-04-05

The hexosamine biosynthesis pathway (HBP) branches from glycolysis and forms UDP-GlcNAc, the moiety for O-linked β-GlcNAc (O-GlcNAc) post-translational modifications. An inability to directly measure HBP flux has hindered our understanding of factors regulating protein O-GlcNAcylation. Our goals in this study were (i) validate a LC-MS method that assesses as UDP-GlcNAc (13C)-molar percent enrichment (MPE) concentration (ii) determine whether glucose availability or workload regulate cardiac...

10.1074/jbc.ra119.010565 article EN cc-by Journal of Biological Chemistry 2020-01-09

Triiodothyronine levels decrease in infants and children after cardiopulmonary bypass. We tested the primary hypothesis that triiodothyronine (T3) repletion is safe this population produces improvements postoperative clinical outcome.The TRICC study was a prospective, multicenter, double-blind, randomized, placebo-controlled trial younger than 2 years old undergoing heart surgery with Enrollment stratified by surgical diagnosis. Time to extubation (TTE) outcome. Patients received intravenous...

10.1161/circulationaha.109.926394 article EN Circulation 2010-09-13

Background— A functional polymorphism in the inhibitory IgG-Fc receptor gene Fc γ RIIB influences intravenous immunoglobulin (IVIG) response Kawasaki disease (KD), a vasculitis preferentially affecting coronary arteries children. We tested hypothesis that polymorphisms activating receptors ( RIIA , RIIIA and RIIIB ) also influence susceptibility, IVIG treatment response, artery patients with KD. Methods Results— genotyped using pyrosequencing 443 KD, including 266 trios 150 single...

10.1161/circgenetics.111.962464 article EN Circulation Cardiovascular Genetics 2012-05-08

OBJECTIVES: Patients with Kawasaki disease can develop life-altering coronary arterial abnormalities, particularly in those resistant to intravenous immunoglobulin (IVIg) therapy. We tested the tumor necrosis factor α receptor antagonist etanercept for reducing both IVIg resistance and artery (CA) progression. METHODS: In a double-blind multicenter trial, patients received either (0.8 mg/kg; n = 100) or placebo (n 101) subcutaneously starting immediately after infusion. was primary outcome...

10.1542/peds.2018-3675 article EN PEDIATRICS 2019-05-02

Children with sepsis and multisystem organ failure have downregulated leukocyte gene expression of peroxisome proliferator-activated receptor-α (PPARα), a nuclear hormone receptor transcription factor that regulates inflammation lipid metabolism. Mouse models likewise demonstrated the absence PPARα is associated decreased survival injury, specifically heart. Using clinically relevant mouse model early sepsis, we found heart function increases in wild-type (WT) mice over first 24 h but...

10.1152/ajpheart.00457.2016 article EN AJP Heart and Circulatory Physiology 2016-11-23

Atrioventricular septal defects (AVSDs) are a frequent but not universal component of Down syndrome (DS), while AVSDs in otherwise normal individuals have no well-defined genetic basis. The contribution copy number variation (CNV) to specific congenital heart disease (CHD) phenotypes including AVSD is unknown. We hypothesized that de novo CNVs on chromosome 21 might cause isolated sporadic AVSDs, and separately throughout the genome constitute an additional risk factor for patients with DS....

10.1002/ajmg.a.35315 article EN other-oa American Journal of Medical Genetics Part A 2012-04-23

Background Protein posttranslational modifications by O ‐linked β‐N‐acetylglucosamine (O‐GlcNAc) increase with cardiac hypertrophy, yet the functional effects of these changes are incompletely understood. In other organs, O‐GlcNAc promotes adaptation to acute physiological stressors; however, prolonged elevations believed be detrimental. We hypothesize that early O‐GlcNAcylation improves function during initial response pressure overload but sustained established pathological hypertrophy...

10.1161/jaha.118.011260 article EN cc-by-nc-nd Journal of the American Heart Association 2019-05-25
Jill Handisides Danielle Hollenbeck-Pringle Karen Uzark Felicia Trachtenberg Victoria L. Pemberton and 95 more Teresa W. Atz Timothy J. Bradley Elizabeth Cappella Sylvia De Nobele Georgeann Groh Michelle Hamstra Rosalind Korsin Jami C. Levine Bergen Lindauer Aimée Liou Meghan K. Mac Neal Larry W. Markham Tonia Morrison Kathleen Mussatto Aaron K. Olson Mary Ella Pierpont Reed E. Pyeritz Elizabeth Radojewski Mary J. Roman Mingfen Xu Ronald V. Lacro Gail D. Pearson Mario Stylianou Lynn Mahony Lynn A. Sleeper Sharon L. Tennstedt Steven D. Colan Gloria L. Klein Lin T. Guey Lisa Wruck Thomas G. Travison Shan Chen Eric Gerstenberger Tanya Olesker David F. Teitel Jane W. Newburger Martha King Carolyn Dunbar‐Masterson Andrea Posa Quincy Nang Cara Hass Daphne T. Hsu Wyman W. Lai William E. Hellenbrand Beth F. Printz Richard B. Devereux Greysi Sherwood Victoria L. Vetter Stephen M. Paridon Marie M. Gleason Nicole Mirarchi Sandra DiLullo Agbenu Ejembi Ruth Morgan D. Woodrow Benson William L. Border James F. Cnota Haleh Heydarian Jeanne James Kathryn Hogan Lois Bogenschutz Mary Pat Benham Teresa Barnard Page A.W. Anderson Jennifer S. Li Stephanie Burns Wechsler Amanda L. Cook Charles Sang Wesley Covitz Lori Jo Sutton Kari Crawford Summer Roberts Deborah Palmer J. Philip Saul Andrew M. Atz Geoffrey A. Forbus Patricia Infinger Aparna Choudhury LuAnn Minich Richard D. Williams Angela Yetman Marian E. Shearrow Michelle Robinson June Porter Brian W. McCrindle Jennifer Russell Jack M. Colman Svetlana Khaikin Nancy Slater Harry C. Dietz William Ravekes Mary F. Rykiel Elisabeth Sparks Gretchen MacCarrick Jennifer Leadroot

10.1016/j.jpeds.2018.08.061 article EN The Journal of Pediatrics 2018-09-27

Hypertrophic stimuli cause transcription of the proto-oncogene c-Myc (Myc). Prior work showed that myocardial knockout (Myc) attenuated hypertrophy and decreased expression metabolic genes after aortic constriction. Accordingly, we assessed interplay between Myc, substrate oxidation cardiac function during early pressure overload hypertrophy. Mice with specific, inducible Myc (MycKO-TAC) non-transgenic littermates (Cont-TAC) were subjected to transverse constriction (TAC; n = 7/group)....

10.1371/journal.pone.0135262 article EN cc-by PLoS ONE 2015-08-12

Pyruvate produces inotropic responses in the adult reperfused heart. oxidation and anaplerotic entry into tricarboxylic acid (TCA) cycle via carboxylation are linked to stimulation of contractile function. The goals this study were determine if these metabolic pathways operate maintained developing myocardium after reperfusion. Immature male swine (age: 10–18 days) subjected cardiopulmonary bypass (CPB). Intracoronary infusion [2- 13 C]pyruvate (to achieve an estimated final concentration 8...

10.1152/ajpheart.00739.2008 article EN AJP Heart and Circulatory Physiology 2008-10-11

Triiodothyronine (T3) supplementation improves clinical outcomes in infants after cardiac surgery using cardiopulmonary bypass by unknown mechanisms. We utilized a translational model of infant to test the hypothesis that T3 modulates pyruvate entry into citric acid cycle (CAC), thereby providing energy support for improved function ischemia-reperfusion (I/R). Neonatal piglets received intracoronary [2-(13)Carbon((13)C)]pyruvate 40 min (8 mM) during control aerobic conditions (control) or...

10.1152/ajpheart.00959.2011 article EN AJP Heart and Circulatory Physiology 2011-12-17
Coming Soon ...